N/A
N=26
The Effects of Different Flow Settings on Lung Impedance
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT06228703 ↗Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Change in End-expiratory Lung Impedance From Baseline Measured by Electrical Impedance Tomography (EIT) — 9; 74; 132; 7 Change in EELI (arbitrary units)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- High-flow nasal cannula device with flow setting at 40 L/min or higher (Device)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Rush University Medical Center
- Primary completion
- Oct 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in End-expiratory Lung Impedance From Baseline Measured by Electrical Impedance Tomography (EIT) |
9; 74; 132; 7; 71; 111 | — |
| SECONDARY Changes in Respiratory Rates Compared to Baseline |
-1.6; -3.7; -5.0; -3.1; -3.1; -4.8 | — |
| SECONDARY Subject's Comfort Level |
9; 8; 7; 9; 8; 8 | — |
Summary
This prospective, randomized crossover trial will enroll adult healthy volunteers. Initially, the subject's peak inspiratory flow will be measured using a mask connected with a respiratory monitor. Subsequently, the volunteers will undergo HFNC treatment at different flow settings while their peak inspiratory flow will be continuously monitored. The primary outcome of this study is the lung aeration with different flow settings. Secondary outcomes include the lung aeration with different devices, subject's comfort at different flow settings, and the correlation between the subject's peak inspiratory flow measured by HFNC and by a mask connected with a respiratory monitor.
Eligibility Criteria
Inclusion Criteria
- Healthy volunteers between 21-65 years old
Exclusion Criteria
- Chronic pulmonary diseases, including COPD, interstitial lung disease, cystic fibrosis, etc.
- Uncontrolled asthma;
- Pregnancy
- Subjects who have cold/flu symptoms (sore throat, runny nose, fever, chills, coughing)
- Nose abnormalities that can affect the functionality of the nasal prongs
Data sourced from ClinicalTrials.gov (NCT06228703). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.